These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. Stevens TL, Burnett JC, Kinoshita M, Matsuda Y, Redfield MM. J Clin Invest; 1995 Mar 06; 95(3):1101-8. PubMed ID: 7883958 [Abstract] [Full Text] [Related]
8. Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure. Solter P, Sisson D, Thomas W, Goetze L. J Pharmacol Exp Ther; 2000 Jun 06; 293(3):989-95. PubMed ID: 10869402 [Abstract] [Full Text] [Related]
9. Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure. Kos T, Pacher R, Wimmer A, Bojic A, Hülsmann M, Frey B, Mayer G, Yilmaz N, Skvarilova L, Spinar J, Vitovec J, Toman J, Woloszcuk W, Stanek B. Wien Klin Wochenschr; 1998 Feb 13; 110(3):89-95. PubMed ID: 9553203 [Abstract] [Full Text] [Related]
10. Role of endogenous atrial natriuretic peptide in chronic anemia in the ovine fetus: effects of a non-peptide antagonist for atrial natriuretic peptide receptor. Silberbach M, Woods LL, Hohimer AR, Shiota T, Matsuda Y, Davis LE. Pediatr Res; 1995 Nov 13; 38(5):722-8. PubMed ID: 8552440 [Abstract] [Full Text] [Related]
12. Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure. Ma J, Peng A, Lin S. Chin Med J (Engl); 1998 Jan 13; 111(1):17-23. PubMed ID: 10322646 [Abstract] [Full Text] [Related]
13. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure. Liu C, Chen Y, Kang Y, Ni Z, Xiu H, Guan J, Liu K. J Pharmacol Exp Ther; 2011 Oct 13; 339(1):203-9. PubMed ID: 21737535 [Abstract] [Full Text] [Related]
15. Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway. Yamamoto T, Wada A, Tsutamoto T, Ohnishi M, Horie M. J Cardiovasc Pharmacol; 2004 Nov 13; 44(5):596-600. PubMed ID: 15505498 [Abstract] [Full Text] [Related]
16. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC. J Am Soc Nephrol; 2006 Oct 13; 17(10):2742-7. PubMed ID: 16928803 [Abstract] [Full Text] [Related]